WO2024040332A1 - Formulations et méthodes de traitement de la cellulite - Google Patents

Formulations et méthodes de traitement de la cellulite Download PDF

Info

Publication number
WO2024040332A1
WO2024040332A1 PCT/CA2023/051074 CA2023051074W WO2024040332A1 WO 2024040332 A1 WO2024040332 A1 WO 2024040332A1 CA 2023051074 W CA2023051074 W CA 2023051074W WO 2024040332 A1 WO2024040332 A1 WO 2024040332A1
Authority
WO
WIPO (PCT)
Prior art keywords
extract
fortified
juice
aronia
tart cherry
Prior art date
Application number
PCT/CA2023/051074
Other languages
English (en)
Inventor
Sakwinder NARWAL
Miodrag ANDRIC
Katarina SAVIKIN
Jelena ZIVKOVIC
Maria GLIBETIC
Original Assignee
Vana Health Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vana Health Inc. filed Critical Vana Health Inc.
Priority to PCT/CA2023/051084 priority Critical patent/WO2024040334A1/fr
Priority to PCT/CA2023/051104 priority patent/WO2024040336A1/fr
Publication of WO2024040332A1 publication Critical patent/WO2024040332A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
    • A61K36/736—Prunus, e.g. plum, cherry, peach, apricot or almond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/06—Preparations for care of the skin for countering cellulitis

Definitions

  • the present invention relates to the treatment of cellulite and, in particular, to nutraceutical and dietary supplement compositions comprising Aronia juice fortified with Aronia extract, and tart cherry juice fortified with tart cherry extract, for the treatment of cellulite.
  • Cellulite is a condition that primarily occurs in 80-90% of post-adolescent women and has also been seen in men. Cellulite is believed to result from herniation of subcutaneous fat without fibrous connective tissue and manifests as an irregular, dimpled appearance of the skin. Cellulite typically appears on the thighs, buttocks, and abdomen, and has been described as resulting in an orange peel textured appearance. The etiology of cellulite is multifactorial including structural, genetic, and endocrine abnormalities. Contributing factors have been identified as poor peripheral circulation, edema, fibrosis, and altered lipocytes metabolism.
  • Grade 1 is characterized by smooth skin without any dimpling upon standing and laying down, but the skin adopts a mattress-like (orange peel) configuration upon pinching, which forces the fat into the reticular and papillary dermis.
  • Grade 2 is characterized by a mattresslike appearance of cellulite present upon standing but disappears when the subject is in the supine position.
  • Grade 3 cellulite can be found in subjects that exhibit skin dimpling upon standing and while they are in the supine position, which can be exacerbated by pinching the skin (Mirrashed F, Sharp JC, Krause V, Morgan J, Tomanek B. Pilot study of dermal and subcutaneous fat structures by MRI in individuals who differ in gender, BMI, and cellulite grading. Skin Res Technol. 2004;10: 161-8).
  • nutraceuticals have received considerable interest due to potential nutritional and therapeutic effects confirmed by studies showing promising results for these compounds in various pathological complications including for treating cellulite.
  • the key to the therapeutic efficacy of nutraceuticals is bioavailability and absorption of the active ingredients of the nutraceutical. Specifically, bioavailability is dependent on the absorption of the nutraceutical’s micronutrients by the epithelial layer of the gut, and the chemical and biochemical transformations into epithelial cells. These processes are endogenous factors that greatly influence the bioavailability of nutraceuticals.
  • An object of the present invention is to provide formulations and methods for treating cellulite.
  • a composition comprising Aronia juice fortified with Aronia extract in combination with tart cherry juice fortified with tart cherry extract.
  • the composition of the present invention further comprises one or more additional nutraceuticals.
  • composition comprising Aronia juice fortified with Aronia extract in combination with tart cherry juice fortified with tart cherry extract, wherein said juices and extracts interact to enhance bioavailability of polyphenols and/or polyphenol gut metabolites from said extracts.
  • composition comprising Aronia juice fortified with Aronia extract in combination with tart cherry juice fortified with tart cherry extract, wherein said juices and extracts interact to enhance anti-cellulite efficacy.
  • a formulation for the treatment of cellulite comprising Aronia juice fortified with Aronia extract, and tart cherry juice fortified with tart cherry extract.
  • the anti-cellulite formulation comprises Aronia juice fortified with Aronia extract in combination with tart cherry juice fortified with tart cherry extract, and one or more additional nutraceuticals selected from the group consisting of red beet extract, rosehip extract, chamomile extract, Melissa officinalis, lemon balm extract, lion’s mane mushroom extract, reishi mushroom extract, parsley, cannabidiol (CBD), and a combination thereof.
  • a method for the treatment of cellulite in a subject comprising administering a therapeutically effective amount of a composition comprising Aronia juice fortified with Aronia extract, and tart cherry juice fortified with tart cherry extract, wherein said composition enhances the bioavailability of polyphenols and/or polyphenol gut metabolites from said extracts.
  • the said juices and extracts interact to enhance anticellulite efficacy.
  • the anti-cellulite composition comprises Aronia juice fortified with Aronia extract in combination with tart cherry juice fortified with tart cherry extract, and one or more additional nutraceuticals selected from the group consisting of red beet extract, rosehip extract, chamomile extract, Melissa officinalis, lemon balm extract, lion’s mane mushroom extract, reishi mushroom extract, parsley, cannabidiol (CBD), and a combination thereof.
  • additional nutraceuticals selected from the group consisting of red beet extract, rosehip extract, chamomile extract, Melissa officinalis, lemon balm extract, lion’s mane mushroom extract, reishi mushroom extract, parsley, cannabidiol (CBD), and a combination thereof.
  • a composition comprising Aronia juice fortified with Aronia extract, and tart cherry juice fortified with tart cherry extract for the preparation of an oral nutraceutical for the treatment of cellulite in a subject, wherein said composition enhances the bioavailability of polyphenols and/or polyphenol gut metabolites from said extracts.
  • the said juices and extracts interact to enhance anti-cellulite efficacy.
  • a composition comprising Aronia juice fortified with Aronia extract, and tart cherry juice fortified with tart cherry extract for the preparation of an oral nutraceutical for the treatment of cellulite in a subject, wherein said composition enhances the bioavailability of polyphenols and/or polyphenol gut metabolites from said extracts.
  • the said juices and extracts interact to enhance anti-cellulite efficacy.
  • Figure 1 presents an illustration of the systemic effects resulting from the enhanced bioavailability and absorption of the polyphenol gut metabolites elicited by the composition according to embodiments of the present invention.
  • Figure 2 is a graph presenting changes in diastolic blood pressure across three time points (baseline (TO), 3 weeks (Tl) and 3 months (T2) of aronia (chokeberry )/tart cherry core formulation consumption).
  • the graph represents results of repeated measures ANOVA of normalized data, presented as relative change from TO. **p ⁇ 0.01, compared to TO; #, p ⁇ 0.05, compared to Tl.
  • Figure 3 presents changes in total body water of right leg (A), left leg (B), Intracellular water of right leg (C), left leg (D), extracellular water of right leg (E) and left leg (F) across three time points (baseline (TO), 3 weeks (Tl) and 3 months (T2) of aronia (chokeberry )/tart cherry core formulation consumption).
  • the graphs represent repeated measures ANOVA analysis of normalized data, presented as relative change from TO. **p ⁇ 0.01, compared to TO; #, p ⁇ 0.05, compared to Tl.
  • Figure 6 presents the effect of 3-month core formulation consumption on oxidative stress/antioxidant defense parameters.
  • n 17 subjects; data analyzed by paired t-test or Wilcoxon signed-rank test. All data are not statistically significant, p>0.05.
  • Figure 7 presents the % reduction in thickness of dermis and subcutaneous tissue.
  • the hatched column represents subjects treated with Formulation A and B for 32 days, and the solid columns represent subjects treated with OCJ for 45 days and 90 days.
  • the trend line shows the rate of anti -cellulite efficacy.
  • Figure 8 presents the % reduction in thickness of subcutaneous tissue.
  • the hatched column represents subjects treated with Formulation A and B for 32 days, and the solid columns represent subjects treated with OCJ for 45 days and 90 days.
  • the trend line shows the rate of anti -cellulite efficacy.
  • Figure 9 presents the % reduction in thickness of dermis and epidermis tissue.
  • the hatched column represents subjects treated with Formulation A and B for 32 days, and the solid columns represent subjects treated with OCJ for 45 days and 90 days.
  • the trend line shows the rate of anti -cellulite efficacy.
  • Figure 10 presents the % reduction in the length of subcutaneous fascicles.
  • the hatched column represents subjects treated with Formulation A and B for 32 days, and the solid columns represent subjects treated with OCJ for 45 days and 90 days.
  • the trend line shows the rate of anti -cellulite efficacy.
  • Figure 11 presents the % reduction in the subjects with edema.
  • the hatched column represents subjects treated with Formulation A and B for 32 days, and the solid columns represent subjects treated with OCJ for 45 days and 90 days.
  • the trend line shows the rate of anti-cellulite efficacy.
  • Polyphenols are micronutrients found in a wide range of food sources that have gained particular attention for their antioxidant properties and their role in the prevention of various diseases associated with oxidative stress, such as cancer and cardiovascular and neurodegenerative diseases. Polyphenols, which constitute the active substances found in many medicinal plants, have also been found to modulate the activity of a wide range of enzymes and cell receptors.
  • polyphenols More than 8,000 types have been identified. They can be further categorized into 4 main groups: (i) flavonoids which account for around 60% of all polyphenols and include quercetin, kaempferol, catechins, apigenin, fisetin, proanthocyanidins, and anthocyanins; (ii) phenolic acids which account for around 30% of all polyphenols and include stilbenes and lignans; (iii) polyphenolic amides which include capsaicinoids and avenanthramides; and (iv) other polyphenols which include resveratrol, ellagic acid, ell agi tannins, resveratrol, urolithin A, curcumin, and lignans.
  • flavonoids which account for around 60% of all polyphenols and include quercetin, kaempferol, catechins, apigenin, fisetin, proanthocyanidins, and anthocyanins
  • Anthocyanins in particular have been suggested as possibly having a beneficial effect in the prevention and treatment of cellulite.
  • the effectiveness of polyphenols in treating cellulite is limited by its bioavailability when ingested.
  • the health effects of polyphenols depend on their bioavailability.
  • There are a number of factors that affect the absorption of polyphenols in particular, metabolism of the polyphenols by intestinal and hepatic enzymes, catabolism of polyphenols and the production of active metabolites by intestinal microflora, and intestinal absorption, all affect the absorption of polyphenols and the polyphenol metabolites.
  • nutraceutical compositions are described that are believed to unexpectedly enhance the bioavailability of polyphenols and the polyphenol gut metabolites.
  • polyphenols and the polyphenol gut metabolites are made more bioavailable in compositions that include pure fruit juice that has the full spectrum of fruit sugars, nutrients, vitamins and minerals to aid in nutrient metabolism by intestinal microflora, such as Coriobacteriia (Eggerthellaceae).
  • the nutraceutical compositions of the present invention enhance antioxidant bioavailability in the gut by combining nutrient-rich and polyphenol- high Aronia and tart cherry juice.
  • the nutraceutical compositions comprise Aronia and tart cherry juices that are further fortified with Aronia and tart cherry extract which together enhance polyphenol bioavailability.
  • the nutraceutical compositions comprise a combination of Aronia juice fortified with Aronia extract in combination with tart cherry juice fortified with tart cherry extract.
  • the nutraceutical compositions result in an increase in n3 and a decrease in n6 polyunsaturated fatty acids (PUFAs) in endothelium and vascular wall cell membranes.
  • PUFAs polyunsaturated fatty acids
  • the components of the nutraceutical compositions interact to ultimately lead to increased cell membrane fluidity through phospholipid restructuring. According to certain embodiments, this restructuring of the vascular wall cell membrane further enhances the intestinal absorption of micronutrients and bioactive phytochemicals.
  • the nutraceutical compositions described herein result in stabilization of the permeability of the gut wall thereby reducing the loss of polyphenol gut metabolites, and thus increasing the amount of bioactive components to be absorbed by the gut epithelium and underlying vasculature.
  • the nutraceutical compositions result in the lowering of zonulin production that modulates the permeability of tight junctions between cells of the gut wall to stabilize gut wall permeability.
  • the compositions of the present invention are combined with additional nutraceuticals to enhance their absorption.
  • the compositions comprise Aronia juice fortified with Aronia extract in combination with tart cherry juice fortified with tart cherry extract, and further in combination with additional nutraceuticals. It is contemplated that the additional nutraceuticals can include any nutraceutical of interest.
  • the nutraceutical compositions comprise Aronia juice fortified with Aronia extract, and tart cherry juice fortified with tart cherry extract, in combination with one or more extracts.
  • the one or more extracts can include, for example, red beet extract, rosehip extract, chamomile extract, lemon balm extract, lion’s mane mushroom extract, reishi mushroom extract, resveratrol extract, quercetin extract, fisetin extract, berberine extract, urolithin A, NMN, Ca-AKG, spermidine extract, TMG, and/or cannabidiol (CBD).
  • red beet extract rosehip extract, chamomile extract, lemon balm extract, lion’s mane mushroom extract, reishi mushroom extract, resveratrol extract, quercetin extract, fisetin extract, berberine extract, urolithin A, NMN, Ca-AKG, spermidine extract, TMG, and/or cannabidiol (CBD).
  • the compositions comprise Aronia juice fortified with Aronia extract, and tart cherry juice fortified with tart cherry extract, in combination with, for example, red beet extract, lion’s mane mushroom extract, and/or rosehip extract.
  • the compositions comprise Aronia juice fortified with Aronia extract, and tart cherry juice fortified with tart cherry extract, in combination with, for example, one or more of rosehip extract, chamomile extract, lemon balm extract, reishi mushroom extract, and/or cannabidiol (CBD).
  • CBD cannabidiol
  • compositions of the present invention comprising Aronia juice fortified with Aronia extract in combination with tart cherry juice fortified with tart cherry extract, are therefore contemplated in certain embodiments for use as an absorption-enhancing carrier for micronutrients and bioactive phytochemicals derived from nutraceutical extracts.
  • the present invention provides for the use of the fortified Aronia and tart cherry juice composition prior to consumption of nutraceutical extracts.
  • the present invention provides for the use of the fortified Aronia and tart cherry juice composition as a carrier for additional nutraceutical extracts.
  • the compositions of the present invention enhance the bioavailability of polyphenols to treat, or reduce the appearance of, cellulite.
  • the term “about” refers to an approximately +/-10% variation from a given value. It is to be understood that such a variation is always included in any given value provided herein, whether or not it is specifically referred to.
  • the words “comprising” (and grammatical variations thereof, such as “comprise” and “comprises”), “having” (and grammatical variations thereof, such as “have” and “has”), “including” (and grammatical variations thereof, such as “includes” and “include”) or “containing” (and grammatical variations thereof, such as “contains” and “contain”) are inclusive or open-ended and do not exclude additional, unrecited elements or method steps.
  • the term “nutraceutical(s)” as used herein refers to a substance that is a food or a part of a food, such as an extract, and contains phytochemicals that are able to induce medical and health benefits.
  • polyphenols refers to the group of plant-derived phytochemicals that can be generally categorized into four main groups: flavonoids, phenolic acids, stilbenes, and lignans.
  • polyphenol gut metabolites refers to the polyphenol metabolites of the gut microbiota.
  • subject refers to both human and non-human animals.
  • anti-cellulite refers to the effect of diminishing, reducing, minimizing, or eliminating, the appearance of cellulite to improve the texture of the skin.
  • the present invention discloses a composition which comprises Aronia juice fortified with Aronia extract in combination with tart cherry juice fortified with tart cherry extract.
  • the combination of the extracts with the corresponding juice enhances the bioavailability of the polyphenol gut metabolites to treat, or reduce the appearance of, cellulite.
  • the composition may also comprise additional polyphenolcontaining nutraceutical extracts, wherein said composition further enhances the treatment, or reduction in the appearance, of cellulite.
  • Aronia also known as chokeberry
  • Aronia is known to contain very high concentrations of polyphenols having antioxidant and radical scavenging properties.
  • Aronia is a deciduous shrub which belongs to the plant family Rosaceae.
  • Aronia melanocarpa black chokeberry
  • Aronia arbutifolia red chokeberry
  • Aronia x prunifolia purple chokeberry
  • the Aronia extract and juice originate from an Aronia species which is pharmaceutically and nutraceutically acceptable or is a mixture of different pharmaceutically or nutraceutically acceptable Aronia species.
  • Aronia species that may be used include, but are not limited to A. melanocarpa, A.
  • the extract and juice are from Aronia melanocarpa.
  • the extract and juice are from Aronia melanocarpa rubinia.
  • the polyphenol content may vary depending on the maturity of the Aronia berries and the growing conditions of the plant.
  • the Aronia plant and fruit may be obtained from various parts of the world, including northern Europe and North America.
  • the Aronia extract and juice are derived from the fruit of A. melanocarpa, which may contain between 500 to 2000 mg of polyphenol per 100 mL of juice.
  • the polyphenol content is between 400 to 900 mg per 100 mL of juice.
  • the polyphenol content is between 600 to 900 mg per 100 mL of juice.
  • the Aronia extract may be derived from the whole fruit or from parts of the fruit.
  • the extract may be produced from the pomace of the fruit, fresh fruit, dried fruit, or fruit juice.
  • the Aronia extract may be obtained according to any suitable extraction method.
  • the Aronia extract is prepared by ultrasound, microwave, and pressure assisted extraction.
  • the Aronia extract is prepared by solvent (ethanol) extraction and the solvent evaporated according to methods known in the art to produce a dry, water-soluble, extract.
  • the Aronia juice may be prepared from the whole fruit or from parts of the fruit.
  • the Aronia juice is prepared from the whole fruit in order to retain the full spectrum of fruit sugars, nutrients, vitamins and minerals found in the whole fruit juice.
  • the Aronia juice may be obtained according to any suitable juice extraction method.
  • the Aronia juice can be prepared by known methods of steam extraction, hot press extraction, cold press extraction, with or without macerating enzyme treatment.
  • the Aronia juice is prepared at low temperatures to maintain the integrity of the micronutrients and phytochemicals in the juice.
  • the Aronia juice is prepared by cold press extraction.
  • the whole Aronia fruit is pressed without heat to allow the release of polyphenols and other berry bioactives from the berry skin.
  • the Aronia juice is further pasteurized or sterilized at low temperatures.
  • the Aronia juice is fortified with Aronia extract.
  • the Aronia extract is a liquid concentrate and is combined with the Aronia juice.
  • the Aronia extract is a dry powder that is dissolved in the Aronia juice.
  • the fortified Aronia juice comprises from at least about 100 mg to about 4000 mg of Aronia extract per 100 mL of Aronia juice.
  • the fortified Aronia juice comprises from at least about 200 mg to about 3500 mg, from at least about 300 mg to about 3000 mg, from at least about 400 mg to about 2500 mg, from at least about 500 mg to about 2000 mg, from at least about 600 mg to about 1500 mg, and from at least about 700 mg to about 1000 mg of Aronia extract per 100 mL of Aronia juice.
  • the fortified Aronia juice comprises about 500 mg of Aronia extract per 100 ml of Aronia juice.
  • the fortified Aronia juice comprises about 1,000 mg to about 3,000 mg of Aronia extract per 100 ml of Aronia juice.
  • the fortified Aronia juice of the present invention comprises Aronia extract in a concentration from at least about 1 mg/mL to about 40 mg/mL, from about 2 mg/mL to about 35 mg/mL, from about 3 mg/mL to about 30 mg/mL, from about 4 mg/mL to about 25 mg/mL, and from about 6 mg/mL to about 15 mg/mL.
  • Tart cherry, sour cherry, or also referred to as dwarf cherry is a species of Prunus in the subgenus Cerasus of the plant family Rosaceae. Tart cherries have been shown to be a source of several beneficial micronutrients, particularly vitamin C, anthocyanins, and melatonin. According to certain embodiments, the Malawin Oblacinska variety of tart cherry is identified as a suitable variety of tart cherry juice and/or extract.
  • the tart cherry extract may be derived from the whole fruit or from parts of the fruit.
  • the extract may be produced from the pomace of the fruit, fresh fruit, dried fruit, or fruit juice.
  • the tart cherry extract may be obtained according to any suitable extraction method.
  • the tart cherry extract is prepared by ultrasound, microwave, and pressure assisted extraction.
  • the tart cherry extract is prepared by solvent (ethanol) extraction and the solvent evaporated according to methods known in the art to produce a dry, water- soluble, extract.
  • the tart cherry juice may be prepared from the whole fruit or from parts of the fruit.
  • the tart cherry juice is prepared from the whole fruit in order to retain the full spectrum of fruit sugars, nutrients, vitamins and minerals found in the whole fruit juice.
  • the tart cherry juice may be obtained according to any suitable juice extraction method.
  • the tart cherry juice can be prepared by known methods of steam extraction, hot press extraction, cold press extraction, with or without macerating enzyme treatment.
  • the tart cherry juice is prepared at low temperatures in order to maintain the integrity of the micronutrients and phytochemicals in the juice.
  • the tart cherry juice is prepared by cold press extraction.
  • the whole tart cherry fruit is pressed without heat to allow the release of polyphenols and other bioactives from the skin of the fruit.
  • the tart cherry juice is further pasteurized or sterilized at low temperatures.
  • the tart cherry juice is fortified with tart cherry extract.
  • the tart cherry extract is a liquid concentrate and is combined with the tart cherry juice.
  • the tart cherry extract is a dry powder that is dissolved in the tart cherry juice.
  • the fortified tart cherry juice comprises from at least about 100 mg to about 5000 mg of tart cherry extract per 100 mL of tart cherry juice.
  • the fortified tart cherry juice comprises from at least about 50 mg to about 4500 mg, from at least about 150 mg to about 3000 mg, from at least about 375 mg to about 2500 mg, from at least about 500 mg to about 2000 mg, from at least about 600 mg to about 1500 mg, and from at least about 700 mg to about 1000 mg of tart cherry extract per 100 mL of tart cherry juice.
  • the fortified tart cherry juice comprises about 1,000 mg to about 3,000 mg of tart cherry extract per 100 mL of tart cherry juice.
  • the fortified tart cherry juice of the present invention comprises tart cherry extract in a concentration from at least about 1 mg/mL to about 50 mg/mL, from about 0.5 mg/mL to about 25 mg/mL, from about 5 mg/mL to about 20 mg/mL, from about 6 mg/mL to about 15 mg/mL, and from about 7 mg/mL to about 10 mg/mL.
  • the composition of the present invention is prepared by combining the Aronia-extract-fortified Aronia juice and the tart cherry-extract-fortified tart cherry juice.
  • the composition comprises a volume ratio of fortified Aronia juice to fortified tart cherry juice in a 1 : 1, 2: 1, 3: 1, 4: 1, 5: 1, 6: 1, 7: 1, 8: 1, 9: 1, or 10: 1 volume ratio.
  • the composition comprises a volume ratio of fortified Aronia juice to fortified tart cherry juice in a 1 : 1, 2: 1, or 4: 1 volume ratio.
  • the composition comprises a volume ratio of fortified tart cherry juice to fortified Aronia juice in a 1 : 1, 2: 1, 3: 1, 4: 1, 5: 1, 6:1, 7: 1, 8: 1, 9: 1, or 10: 1 volume ratio.
  • the composition comprises a volume ratio of fortified tart cherry juice to fortified Aronia juice in a 1 : 1, 2: 1, or 4: 1 volume ratio.
  • the composition of Aronia- extract-fortified Aronia juice and tart cherry-extract-fortified tart cherry juice comprises from at least about 100 mg to about 4000 mg of Aronia extract and from at least about 20 mg to about 5000 mg of tart cherry extract per 100 mL.
  • the composition comprises from at least about 200 mg to about 3500 mg, from at least about 300 mg to about 3000 mg, from at least about 400 mg to about 2500 mg, from at least about 500 mg to about 2000 mg, from at least about 600 mg to about 1500 mg, or from at least about 700 mg to about 1000 mg of Aronia extract per 100 mL, and from at least about 50 mg to about 4500 mg, from at least about 150 mg to about 3000 mg, from at least about 375 mg to about 2500 mg, from at least about 500 mg to about 2000 mg, from at least about 600 mg to about 1500 mg, or from at least about 700 mg to about 1000 mg of tart cherry extract per 100 mL.
  • the composition comprises about 2000 mg of Aronia extract and about 1500 mg of tart cherry extract per 100 mL.
  • the combination of Aronia and tart cherry extracts with the corresponding juice provides a synergistic effect that enhances the bioavailability of polyphenol and/or polyphenol gut metabolites, and enhances absorption of micronutrients and bioactive phytochemicals.
  • the composition of Aronia juice fortified with Aronia extract, and tart cherry juice fortified with tart cherry extract may also comprise additional nutraceutical extracts.
  • the additional extracts comprise additional polyphenols.
  • the additional extracts comprise anti-cellulite bioactive agents. It is contemplated that the increased absorption of the micronutrients and bioactive phytochemicals, when combined with the composition of fortified Aronia and tart cherry juice, results in an enhanced beneficial effect for treating, or reducing the appearance of, cellulite.
  • the additional micronutrients and bioactive phytochemicals may be provided as one or more active compounds from the group of vitamins, minerals, and trace minerals.
  • the additional micronutrient and bioactive phytochemicals may be provided in synthetic or plant-derived form.
  • the additional micronutrients and bioactive phytochemicals comprise polyphenols.
  • the additional micronutrients and bioactive phytochemicals are provided as one or more nutraceutical extracts.
  • the additional micronutrients and bioactive phytochemicals may be provided as any one or more of the following nutraceutical extracts.
  • Beetroot extract has a high nitrate and antioxidant (betanin) content.
  • Beetroot extract may increase in vivo nitric oxide (NO) bioavailability, enhance endothelial function, improve blood flow and enhance physical performance, as well as combat damaging reactive oxygen species.
  • NO nitric oxide
  • Rosehip extract has a particularly high vitamin C, carotenoid (lycopene), and polyphenol content, which are all beneficial in fighting inflammation and protecting the immune system from viral and bacterial infection.
  • Chamomile extract is traditionally used for its calming effects and is thought to aid in combating depression and anxiety with its unique content of apigenin, an antioxidant that promotes sleepiness, improves sleep quality and reduces insomnia.
  • apigenin an antioxidant that promotes sleepiness, improves sleep quality and reduces insomnia.
  • chamomile extract is thought to improve gastrointestinal and cardiovascular health, and lower blood pressure.
  • Lemon balm (Melissa officinalis) is a powerful herb from the mint family that is thought to reduce stress and anxiety, and improve mood and sleep quality.
  • Lemon balm extract is high in flavonoids, phenolic compounds, as well as antioxidants such as rosmarinic and gallic acid, which all help to combat inflammation, promote gastrointestinal health and boost cognitive function.
  • Lion’s mane mushroom is a medicinal mushroom believed to offer a range of health benefits, including reduced inflammation and improved cognitive and heart health.
  • Reishi mushroom is a polypore fungus belonging to the genus Ganoderma (Ganoderma lucidum) and is considered to be a medicinal mushroom in many Asian cultures for its health-promoting effects. Reishi mushroom is thought to have immunomodulatory, renoprotective, anti-inflammatory, and hepatoprotective properties.
  • parsley The two main groups of parsley are curly leaf (i.e., . crispum crispum group; syn. P. crispum var. crispum) and Italian, or flat leaf (i.e., P. crispum neapolitanum group; syn. P. crispum var. neapolitanum). Of these, the neapolitanum group more closely resembles the natural wild species. It contains a variety of B vitamins including B-5 and B- 2. Parsley may also contain more vitamin K than any other herb since it has more than 1300 percent of the recommended daily intake. Parsley can be used to treat conditions like: water edema, high blood pressure, digestion.
  • CBD Cannabidiol
  • CBD particularly from hemp, has a variety of vitamins and minerals such as vitamins A, C, E and B complex, as well as zinc, potassium, iron, calcium, essential amino acids, and omega 3 and 6 fatty acids. CBD has been reported to reduce anxiety, stress and depression, as well as improve sleep quality, pain management and overall wellness.
  • the composition of Aronia- extract-fortified Aronia juice and tart cherry-extract-fortified tart cherry juice further includes one or more additional nutraceuticals selected from red beet extract, rosehip extract, chamomile extract, Melissa officinalis, lemon balm extract, lion’s mane mushroom extract, reishi mushroom extract, parlsley, cannabidiol (CBD), or any combination of these extracts.
  • additional nutraceuticals selected from red beet extract, rosehip extract, chamomile extract, Melissa officinalis, lemon balm extract, lion’s mane mushroom extract, reishi mushroom extract, parlsley, cannabidiol (CBD), or any combination of these extracts.
  • the one or more additional nutraceutical extracts are added to the Aronia-extract-fortified Aronia juice and tart cherry-extract-fortified tart cherry juice composition in the following ranges, from at least about 50 mg to 5000 mg of red beet extract, from at least about 20 mg to 5000 mg of rosehip extract, from at least about 10 mg to 2000 mg of chamomile extract, from at least about 10 mg to 3000 mg of Melissa officinalis, from at least about 10 mg to 4000 mg of lemon balm extract, from at least about 100 mg to 1500 mg of lion’s mane mushroom extract, from at least about 100 mg to 1500 mg of reishi mushroom extract, and/or from at least about 1 mg to 300 mg of cannabidiol (CBD) per 100 mL.
  • CBD cannabidiol
  • the composition includes one or both of the additional nutraceutical extracts selected from red beet extract, lion’s mane mushroom extract, and/or rosehip extract.
  • the composition includes from about 50 mg to 5000 mg of red beet extract, and/or from about 20 mg to 5000 mg of rosehip extract, and/or from about 100 mg to 1500 mg of lion’s mane mushroom extract per 100 mL.
  • the Aronia-extract-fortified Aronia juice and tart cherry-extract- fortified tart cherry juice composition further includes about 1000 mg of red beet extract, and/or about 1000 mg of rosehip extract, and/or about 1000 mg of lion’s mane mushroom extract, and/or about 300-1000 mg of wild form of parsley extract per 100 mL.
  • the Aronia-extract- fortified Aronia juice and tart cherry-extract-fortified tart cherry juice composition further includes one or more additional nutraceutical extracts that comprise one or more of rosehip extract, chamomile extract, reishi mushroom extract, and lemon balm extract.
  • the one or more additional nutraceutical extracts are added to the Aronia- extract-fortified Aronia juice and tart cherry-extract-fortified tart cherry juice composition in the following ranges, from at least about 20 mg to 5000 mg of rosehip extract, from at least about 10 mg to 2000 mg of chamomile extract, from at least about 100 mg to 1500 mg of reishi mushroom extract, and/or from at least about 10 mg to 4000 mg of lemon balm extract per 100 mL.
  • the Aronia-extract-fortified Aronia juice and tart cherry-extract-fortified tart cherry juice composition further includes about 1000 mg of rosehip extract, 700 mg of chamomile extract, 1000 mg of reishi mushroom extract, and/or 500 mg of lemon balm extract, and/or about 300-1000 mg of wild form of parsley extract per 100 mL.
  • the formulation comprises Aronia-extract-fortified Aronia juice, tart cherry-extract-fortified tart cherry juice, with at least about 50 mg to 5000 mg of red beet extract, about 20 mg to 5000 mg of rosehip extract, about 10 mg to 2000 mg of chamomile extract, and 100 mg to 1500 mg of lion’s mane mushroom extract per 100 mL.
  • the formulation comprises Aronia-extract-fortified Aronia juice, tart cherry-extract-fortified tart cherry juice, with at least about 10 mg to 2000 mg of chamomile extract, at least about 10 mg to 4000 mg of lemon balm extract, at least about 100 mg to 1500 mg of reishi mushroom extract per 100 mL.
  • the additional nutraceuticals added to the Aronia-extract-fortified Aronia juice and tart cherry-extract- fortified tart cherry juice composition further includes cannabidiol (CBD).
  • CBD cannabidiol
  • the CBD is added to the composition, according to certain embodiments, in an amount that ranges from at least about 1 mg to 300 mg per 100 mL.
  • the Aronia-extract-fortified Aronia juice and tart cherryextract-fortified tart cherry juice composition includes one or more of from at least about 20 mg to 5000 mg of rosehip extract, from at least about 10 mg to 2000 mg of chamomile extract, from at least about 10 mg to 4000 mg of lemon balm extract, from at least about 100 to 1500 mg of reishi mushroom extract, from at least about 300 tolOOO mg of wild form of parsley, and from at least about 1 mg to 300 mg of cannabidiol (CBD) per 100 mL.
  • rosehip extract from at least about 10 mg to 2000 mg of chamomile extract, from at least about 10 mg to 4000 mg of lemon balm extract, from at least about 100 to 1500 mg of reishi mushroom extract, from at least about 300 tolOOO mg of wild form of parsley, and from at least about 1 mg to 300 mg of cannabidiol (CBD) per 100 mL.
  • CBD cannabidiol
  • the Aronia-extract-fortified Aronia juice and tart cherryextract-fortified tart cherry juice composition further includes one or more additional nutraceuticals selected from about lOOmg to 2,000mg of resveratrol extract, about lOOmg to l,000mg of quercetin extract, about lOOmg to l,000mg of fisetin extract, lOOmg to 3, OOOmg of berberine extract, about lOOmg to 3,000mg of urolithin A, about lOOmg to 3,000mg of NMN, about lOOmg to 3, OOOmg of Ca-AKG, about lOmg to 3, OOOmg of spermidine extract, and/or about lOOmg to 3, OOOmg of TMG.
  • additional nutraceuticals selected from about lOOmg to 2,000mg of resveratrol extract, about lOOmg to l,000mg of quercet
  • the Aronia-extract-fortified Aronia juice and tart cherry-extract-fortified tart cherry juice composition can be formulated as a nutritional supplement for oral consumption.
  • the formulation comprises the Aronia- extract-fortified Aronia juice and tart cherry-extract-fortified tart cherry juice composition as described herein, formulated as an oral supplement.
  • the formulation comprises the Aronia-extract-fortified Aronia juice and tart cherry-extract- fortified tart cherry juice composition in combination with one or more additional nutraceutical extracts as described herein, formulated as an oral supplement.
  • the formulation comprises the Aronia-extract-fortified Aronia juice and tart cherry-extract-fortified tart cherry juice composition in combination with one or more additional polyphenol-containing extract.
  • the composition according to the present invention may be formulated in a liquid form, i.e., for example in the form of solutions, dispersions, emulsions and gels, or in a solid form.
  • the composition is formulated as a capsule, a tablet, a liquid concentrate, a liquid drink, or a powder.
  • the composition is formulated as a liquid drink, syrup, tonic, or jelly.
  • the composition is formulated as an edible solid or an edible semi-solid.
  • the formulation is a powder reconstituted into potable liquid (i.e. water, etc.).
  • additional components can be added to the formulation to provide colour, flavour, texture, scent, etc.
  • the formulation comprises additional components that act as preservatives or stabilize one or more of the ingredients.
  • the present invention provides methods for treating, or reducing the appearance of cellulite.
  • the methods comprise administering to a subject, an amount of the composition described herein to enhance the bioavailability of polyphenols and/or polyphenol gut metabolites to treat, or reduce the appearance of, cellulite.
  • the compositions are administered to a subject to elicit enhanced intestinal absorption of polyphenols and/or the polyphenol gut metabolites in a subject to treat, or reduce the appearance of, cellulite.
  • the compositions are administered to a subject to further enhance the absorption of additional anti -cellulite micronutrients, and/or bioactive phytochemicals, and/or polyphenol-containing extracts, in a subject.
  • the effective amount may be determined by a person skilled in the art using the guidance provided herein and the general knowledge in the art. It will be appreciated that the amount to be administered depends on the subject to be treated taking into account age, weight and other personal conditions.
  • the treatments/preventive administration may be continued as a regimen, e.g., daily, monthly, bimonthly, biannually, annually, or in some other regimen, as determined by the skilled medical practitioner for such time as is necessary.
  • the composition is administered daily, most preferably two or three times a day, for example, morning and evening to maintain the levels of the effective compounds in the body of the subject. To obtain the most beneficial results, the composition may be administered for at least about 30 to about 60 days. These regimens may be repeated periodically.
  • the composition is taken at least once a day for 1 week to 12 months. In other embodiments, the composition is taken at least once a day for 1, 2, 3, or 4 weeks. In further embodiments, the composition is taken at least once a day for 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12 months.
  • compositions in treating, or reducing the appearance of, cellulite in different body parts can be evaluated by standard techniques known in the art. For example, the severity of cellulite in different body parts (arms, legs, buttocks, abdomen) can be visibly assessed and measured using the impedance methodology and for tissue/cellular description by Numberger-Muller cellulite classification scale (Michael H. Gold, 2012 J. German Soc. Dermat. 10:553-558). According to this scale, the appearance of the cellulite is categorized into four grades:
  • Stage 0 No dimpling when the subject is standing and lying. The pinch test reveals “folds and furrows”, but there is no mattress-like appearance.
  • Stage l No dimpling when the subject is standing or lying, but the pinch test reveals the mattress-like appearance.
  • Stage 2 Dimpling appears spontaneously when standing and not lying down.
  • Stage 3 Dimpling is spontaneously positive standing and lying down.
  • the appearance of the subject’s cellulite is assessed for improvement in the appearance of the cellulite according to the Numberger-Muller scale, for example.
  • Other standard techniques may also be employed to assess the composition, including evaluation of efficacy in treating factors related to the development of cellulite including, for example, edema, microcirculation, inflammation, and vasokinetic activity.
  • core formulation fortified aronia-tart cherry formulation
  • the formulation consisted of aronia also known as chokeberry (Aronia melanocarpd) and tart cherry (Primus cerasus) mother juices combined in a 4: 1 ratio (volume/volume) enriched with polyphenol-rich dry extracts from both of these fruits, total of 1000 mg od polyphenols.
  • the parameters observed in this preliminary study include: blood count parameters, markers of kidney and liver function, anthropometric parameters, blood pressure, metabolic parameters (blood lipid profiles, blood sugar), markers of cardiovascular risk, intestinal permeability, inflammatory biomarkers, antioxidant defense parameters and erythrocyte fatty acid profiles. These parameters were monitored to identify the systemic effects resulting from prolonged consumption of the core formulation which reflect the bioavailability and absorption of the polyphenols.
  • Participants included in this study were subjects of both sexes (11 men and 6 women), mean age 43.8 ⁇ 2.2, with no diagnosed cardiovascular disease (CVD), with an elevated body mass index (BMI> 25) or abdominal obesity (waist circumference above >94 cm for men, >80 cm for women), with or without: blood pressure above optimal values (SBP/DBP > 120/80 mm Hg), elevated triglycerides (>1.7 mmol/L or >150 mg/dL), elevated LDL cholesterol (> 2.6 mmol/L or > 100 mg/dL), elevated total-cholesterol (>5.0 mmol/L or >193 mg/dL) and reduced HDL-cholesterol (men ⁇ 1 mmol/L, women ⁇ 1.3 mmol/L). Study participants were not on special dietary regiments (e.g., vegan and vegetarian) and did not report allergy or intolerance to berries or chokeberry/tart cherry formulation components.
  • CVD cardiovascular disease
  • BMI body mass index
  • abdominal obesity weight above >
  • Venous blood was drawn in the morning (8:00-9:00 a.m.) after an overnight fast, at three time points: before the consumption (Baseline, TO), after 3 -weeks (short-term, Tl), and after 3 months (long-term, T2) of core formulation consumption.
  • Blood was collected into the appropriate sample tubes and further processed to obtain serum and plasma samples. Biochemical parameters were determined in fresh serum samples using the clinical biochemistry analyzer. Plasma samples were used to evaluate intestinal permeability and inflammatory parameters by ELISA assays. Whole blood was used to assess hematological parameters by the hematology analyzer and the antioxidant defense parameters by commercial kits. Erythrocyte fatty acid profiles in the total lipid pool were determined by gas chromatography.
  • the hematological parameters assessed include leukocyte count and differential, erythrocyte count, platelet count, hemoglobin concentration, hematocrit (packed cell volume), mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH), mean corpuscular hemoglobin concentration (MCHC).
  • Kidney function was assessed for ability to perform normal functions like clearing waste products (serum urea (BUN), creatinine, uric acid levels) and maintaining the electrolyte balance (serum sodium, potassium, and chloride levels).
  • BUN serum urea
  • creatinine creatinine
  • uric acid levels creatinine, uric acid levels
  • electrolyte balance serum sodium, potassium, and chloride levels
  • liver function was assessed by observing how well the liver is performing its regular function like producing protein (serum albumin, total protein levels) and clearing bilirubin, as well as the measurement of enzymes that liver cells release in response to
  • SUBSTITUTE SHEET damage, including serum alanine transaminase (ALT), aspartate transaminase (AST) and lactate dehydrogenase (LDH).
  • ALT serum alanine transaminase
  • AST aspartate transaminase
  • LDH lactate dehydrogenase
  • Body composition was evaluated using bioelectrical impedance analysis (BIA) - InBody 770 (Inbody Co., LTD, Seoul, Korea). During measurements, subjects wore typical athletic clothing and removed all metal jewelry. Subjects stood on the platform of the device barefoot with the soles of their feet on the electrodes and grasped the unit's handles with their thumb and fingers to maintain direct contact with the electrodes. They remained still for ⁇ 1 min with elbows fully extended, and their shoulder joint abducted to approximately a 30-degree angle.
  • BIOA bioelectrical impedance analysis
  • Blood biomarkers of CVD risk include fibrinogen, homocysteine, and C-reactive protein (CRP) levels.
  • CRP C-reactive protein
  • VCAM-1 vascular cell adhesion protein 1
  • ICM-1 intercellular adhesion molecule 1
  • ECM-1 endothelin-1
  • TNFa tumor necrosis factor alpha
  • IL-6 interleukin 6
  • Oxidative stress/antioxidant defense was evaluated as 1) activities of enzymes involved in antioxidant protection: glutathione peroxidase (GPx), superoxide dismutase (SOD), and catalase (CAT); and 2) index of lipid peroxidation determined as thiobarbituric acid-reactive substances (TBARS) expressed as malondialdehyde (MDA) equivalents.
  • GPx glutathione peroxidase
  • SOD superoxide dismutase
  • CAT catalase
  • TBARS thiobarbituric acid-reactive substances
  • ICAM-1 a marker of endothelial dysfunction
  • plasma zonulin A significant reduction in junctional protein levels, ICAM-1 (a marker of endothelial dysfunction) and plasma zonulin, suggest that long-term consumption of the aronia/tart cherry core formulation improved intestinal permeability leading to tighter cell junctions and less water and nutrient loss. The resulting systemic effects of this were further shown by a significant effect on the total, intra and extracellular water in both legs and lowered diastolic blood pressure, suggesting potential anticellulite and blood pressure modulating effects of the studied formulation.
  • the test drink also showed increased variables associated with anemia and the health of the hemoglobin in the blood (MCH, MCHC) and reduced uric acid levels, a parameter associated with the development of hypertension, metabolic syndrome, and diabetes mellitus. Furthermore, reduced serum levels of CVD risk biomarker homocysteine, and lowered long-term blood glucose levels, were observed.
  • the polyphenol-rich core formulation also showed a tendency to modulate oxid
  • Formulation A Formulation B:
  • composition of these formulations was analyzed using known methods as comprising:
  • Subjects consumed 60 mL of Formulation A in the morning and 60 mL of Formulation B in the evening each day for 32 days, after their meal. During that period, the subjects maintained their regular diet, exercise program and lifestyle.
  • Biochemical parameters blood count with leukocyte formula, total cholesterol, HDL, LDL, triglycerides, glucose, iron, risk factor, atherosclerosis index).
  • Anthropometric parameters body weight, body mass index, fat %, muscle%, visceral fat, basal metabolism.
  • the high-frequency ultrasound examinations were carried out using Toshiba applio XH linear multifocal probe 10 to 14MHz.
  • the ultrasound images obtained were saved on a personal computer, and then analyzed using experimental software.
  • the examinations were performed on the posterior part of the thigh in triplicate, always at the same location.
  • the skin consists of three layers: epidermis, dermis and hypodermis (subcutaneous tissue).
  • the epidermis is the outer, non-vascularized layer, which consists of keratinocytes, Merkel cells (mechanoreceptors), melanocytes (skin color) and Langerhans cells (antigen-presenting cells).
  • Below the epidermis are vascularized layers, the dermis and hypodermis.
  • Dermis is a dense connective tissue, made of collagen, elastic and reticular fibers imbued with blood and lymphatic vessels, as well as sensory and motor nerve fibers.
  • Subcutaneous tissue which is also known as hypodermis, is the inner layer of the skin. It consists of fatty and connective tissues in which larger blood vessels and nerves are located. Subcutaneous tissue acts as an insulator and regulates body temperature. The thickness of this layer varies throughout the body and from person to person.
  • Treatment with Formulation A / Formulation B consumption showed a faster anticellulite effect over OCJ alone, achieving a greater reduction in dermis with subcutaneous tissue thickness in 32 days than OCJ over 90 days (Figure 7).
  • Treatment with Formulation A / Formulation B showed an efficacy rate of 0.47% reduction per day in dermis with subcutaneous tissue thickness, whereas OCJ alone showed an efficacy rate of 0.11% reduction per day.
  • Treatment with Formulation A / Formulation B consumption showed a faster anticellulite effect over OCJ alone, achieving a greater reduction in subcutaneous tissue thickness in 32 days than OCJ over 90 days (Figure 8).
  • Treatment with Formulation A / Formulation B showed an efficacy rate of 0.45% reduction per day in subcutaneous tissue thickness, whereas OCJ alone showed an efficacy rate of 0.10% reduction per day.
  • Treatment with Formulation A / Formulation B consumption showed a faster anticellulite effect over OCJ alone, achieving a greater reduction in dermis and epidermis tissue thickness in 32 days than OCJ over 90 days (Figure 9).
  • Treatment with Formulation A / Formulation B showed an efficacy rate of 0.69% reduction per day in dermis and epidermis thickness, whereas OCJ alone showed an efficacy rate of 0.13% reduction per day. An improvement of over 5 times the efficacy rate of OCJ alone.
  • interstitial edema may impede oxygen diffusion to the skin. Given that a rich microvascular network is located in the dermal layer of the skin, any change in skin blood flow or in the formation of interstitial edema would affect the local tissue tension inside and hence the tissue properties of skin layers in response to external pressure. Edema is an extremely important factor affecting the oxygenation of tissue in that it increases the intercellular spaces, hence causing an increase in the distance for oxygen to diffuse to the most distant cell (Silver IA. Local factors in tissue oxygenation. J Clin Pathol Suppl (R Coll Pathol) 1977;11 :7-13).
  • Echogenicity refers to the ability of tissues and organs to absorb ultrasound. Normal echogenicity is called iso-echogenicity. Liquids have low echogenicity. Therefore, low echogenicity (hypoechoic) is a sign of edema in our study.
  • Results obtained in this study show a marked improvement in the efficacy of improving the morphology of skin and subcutaneous tissue in the regions affected by cellulite under in vivo conditions with Formulations A and B.
  • the anti -cellulite effect of treating subjects with Formulations A and B resulted in a more pronounced and faster acting effect than OCJ alone.

Abstract

L'invention concerne une formulation permettant de traiter ou d'atténuer l'aspect de la cellulite, comprenant une combinaison de jus d'Aronia enrichi avec un extrait d'Aronia, et un jus de cerise acide enrichi avec un extrait de cerise acide.
PCT/CA2023/051074 2022-08-24 2023-08-11 Formulations et méthodes de traitement de la cellulite WO2024040332A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
PCT/CA2023/051084 WO2024040334A1 (fr) 2022-08-24 2023-08-15 Compositions et méthodes pour l'entretien et l'amélioration de la santé vasculaire
PCT/CA2023/051104 WO2024040336A1 (fr) 2022-08-24 2023-08-21 Compositions et méthodes pour la gestion des taux de glycémie pour la prophylaxie du prédiabète et du diabète sucré

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US202263400711P 2022-08-24 2022-08-24
US63/400,711 2022-08-24
US202263400827P 2022-08-25 2022-08-25
US63/400,827 2022-08-25
US202363443657P 2023-02-06 2023-02-06
US63/443,657 2023-02-06

Publications (1)

Publication Number Publication Date
WO2024040332A1 true WO2024040332A1 (fr) 2024-02-29

Family

ID=90011998

Family Applications (3)

Application Number Title Priority Date Filing Date
PCT/CA2023/051074 WO2024040332A1 (fr) 2022-08-24 2023-08-11 Formulations et méthodes de traitement de la cellulite
PCT/CA2023/051084 WO2024040334A1 (fr) 2022-08-24 2023-08-15 Compositions et méthodes pour l'entretien et l'amélioration de la santé vasculaire
PCT/CA2023/051104 WO2024040336A1 (fr) 2022-08-24 2023-08-21 Compositions et méthodes pour la gestion des taux de glycémie pour la prophylaxie du prédiabète et du diabète sucré

Family Applications After (2)

Application Number Title Priority Date Filing Date
PCT/CA2023/051084 WO2024040334A1 (fr) 2022-08-24 2023-08-15 Compositions et méthodes pour l'entretien et l'amélioration de la santé vasculaire
PCT/CA2023/051104 WO2024040336A1 (fr) 2022-08-24 2023-08-21 Compositions et méthodes pour la gestion des taux de glycémie pour la prophylaxie du prédiabète et du diabète sucré

Country Status (1)

Country Link
WO (3) WO2024040332A1 (fr)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6818234B1 (en) * 1999-08-27 2004-11-16 Access Business Group International Llc Dietary food supplement containing natural cyclooxygenase inhibitors and methods for inhibiting pain and inflammation
US20090252796A1 (en) * 2008-04-07 2009-10-08 Mazed Mohammad A Nutritional supplement for the prevention of cardiovascular disease, alzheimer's disease, diabetes, and regulation and reduction of blood sugar and insulin resistance
US8449927B2 (en) * 2007-03-15 2013-05-28 Omnica Gmbh Stabilized anthocyanin compositions
US20130171294A1 (en) * 2010-07-27 2013-07-04 Omniceutica Limited Nutritional Compositions

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6818234B1 (en) * 1999-08-27 2004-11-16 Access Business Group International Llc Dietary food supplement containing natural cyclooxygenase inhibitors and methods for inhibiting pain and inflammation
US8449927B2 (en) * 2007-03-15 2013-05-28 Omnica Gmbh Stabilized anthocyanin compositions
US20090252796A1 (en) * 2008-04-07 2009-10-08 Mazed Mohammad A Nutritional supplement for the prevention of cardiovascular disease, alzheimer's disease, diabetes, and regulation and reduction of blood sugar and insulin resistance
US20130171294A1 (en) * 2010-07-27 2013-07-04 Omniceutica Limited Nutritional Compositions

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ŠAVIKIN KATARINA, MENKOVIĆ NEMANJA, ZDUNIĆ GORDANA, PLJEVLJAKUŠIĆ DEJAN, SPASIĆ SLAVICA, KARDUM NEVENA, KONIĆ-RISTIĆ ALEKSANDRA: "Dietary Supplementation with Polyphenol-Rich Chokeberry Juice Improves Skin Morphology in Cellulite", JOURNAL OF MEDICINAL FOOD, MARY ANN LIEBERT, LARCHMONT, NY,, US, vol. 17, no. 5, 1 May 2014 (2014-05-01), US , pages 582 - 587, XP093144782, ISSN: 1096-620X, DOI: 10.1089/jmf.2013.0102 *
SEYMOUR ET AL.: "Regular Tart Cherry Intake Alters Abdominal Adiposity, Adipose Gene Transcription, and Inflammation in Obesity-Prone Rats Fed a High Fat Diet", J MED FOOD, vol. 12, no. 5, 2009, pages 935 - 942, XP009189080, ISSN: 1557-7600 *

Also Published As

Publication number Publication date
WO2024040334A1 (fr) 2024-02-29
WO2024040336A1 (fr) 2024-02-29

Similar Documents

Publication Publication Date Title
Amagase et al. Lycium barbarum (goji) juice improves in vivo antioxidant biomarkers in serum of healthy adults
Wachtel-Galor et al. Ganoderma lucidum (‘Lingzhi’); acute and short-term biomarker response to supplementation
JP2010528109A (ja) 高麗人参の実抽出物を含有する皮膚外用剤組成物
CN101518336A (zh) 一种具有抗氧化功能的营养食品及其制备方法
CN106580732A (zh) 一种乳液及其制备方法
Chiu et al. Improvement on blood pressure and skin using roselle drink: A clinical trial
KR101160088B1 (ko) 알코올성 지방간과 고지혈증 억제 및 숙취 억제 조성물
CN106692532A (zh) 一种用于燃脂减肥的中药组合物及其贴剂和减肥套装
WO2009097238A1 (fr) Formulations et procédés de réduction de graisse abdominale et de tour de taille
KR100503926B1 (ko) 생체내 유해세균 성장억제용 조성물
WO2024040332A1 (fr) Formulations et méthodes de traitement de la cellulite
KR102581166B1 (ko) 황칠추출물을 포함하는 여드름 개선용 화장료 조성물
EP3991801A1 (fr) Composition pour améliorer l'état de la peau contenant des extraits de plantes
KR101575768B1 (ko) 천연재료를 이용한 피부 보습 보조제 조성물
JP2015050991A (ja) 健康補助食品
Ischak et al. Preliminary Study of Clinical Antidiabetic Activity of Salam Leaves (Eugenia Polyantha) and Sambiloto Leaves (Andrographis Paniculata) In Type 2 Diabetic Patients
Nishimura et al. Effects of daily intake of Harudori-kombu: A randomized, double-blind, placebo-controlled, parallel-group study
JP4585227B2 (ja) 痩身用キット
US11324782B2 (en) Method of preventing obesity using herb ferment
Anna et al. Wine grapes (Vitis vinifera) and wine-based food supplements
TWI719781B (zh) 草本植物發酵物用於製備預防肥胖之組合物的用途
KR101154182B1 (ko) 방광과체질에 처방되는 변비개선용 천연음료 조성물
Khursheed et al. Determination of proximate composition and antioxidant potential of aloe vera gel with the development and sesonsory evaluation of alow vera based drinks
KR101855820B1 (ko) 간 기능 개선 및 스태미나 증진을 위한 건강식품 조성물
Ain et al. Health Benefits of Avocado

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23855921

Country of ref document: EP

Kind code of ref document: A1